Skip header and navigation

3 records – page 1 of 1.

Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040701v2 RR
Question Submitted
April 7, 2020
Date Completed
May 8, 2020
Status
5. Updated review
Research Team
Laboratory
Key Findings
COVID-19 is primarily transmitted by symptomatic patientsand presymptomatic individuals.·Moderate grade evidence estimates that approximately 20% of COVID-19 transmission may bedue to that from presymptomatic individuals.However, estimates range from 6.4% -47%.·Asymptomatic individuals and environmental contaminationappear to contributelessto disease transmission,with estimated proportionsof 6% and 10%, respectivelyfrom modelling studies
Category
Clinical Presentation
Epidemiology
Subject
Transmission
Symptoms
Symptomatic
Asymptomatic
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B; What proportion of disease transmission is due to asymptomatic, pre-symptomatic and symptomatic cases? 2020 May 8; Document no.: LAB040701v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 12 p. (CEST rapid review report)
Similar Reviews
EPM051301 RR
Review History
LAB040701 RR: April 7, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC062201v2 RR
Question Submitted
June 22, 2020
Date Completed
January 22, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer. However, more data are beginning to elucidate the nuances of these risks depending on patient specific factors.
Limited data indicate that pediatric cancer patients are not at a high level of risk of severe outcomes from COVID-19.
Limited evidence indicates some differences in the course and severity of SARS-CoV-2 infection depending on the type of immunosuppressive therapy a patient receives.
Key Findings
Generally speaking, data indicate that adult cancer patients and those who have recently received or are receiving anti-cancer therapy are at a higher risk of severe outcomes and death resulting from COVID-19 compared to those without cancer.
Pediatric cancer populations may not be at the same level of risk as adult populations.
There is not enough evidence at this time to determine if there are differences in the course of SARS-CoV-2 infection in patients receiving chemotherapy vs. those who are not aside from outcomes and severity.
Category
Clinical Presentation
Subject
Chemotherapy
Cancer
Comorbidities
Natural History
Population
All
Priority Level
Level 3 completed within 2-3 days
Cite As
Vanstone, J; Groot, G; Miller, L; Mueller, M. What are the differences in the clinical course of COVID-19 between patients undergoing chemotherapy and otherwise healthy individuals? 2021 Jan 22; Document no.: EOC062201v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Review History
EOC062201 RR: June 29, 2020
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
EOC021901v2 RR
Question Submitted
February 19, 2021
Date Completed
October 29, 2021
Status
5. Updated review
Research Team
EOC
Document Type
Rapid Review
Review Code
EOC021901v2 RR
Question Submitted
February 19, 2021
Date Completed
October 29, 2021
Status
5. Updated review
Research Team
EOC
Updated Key Findings
October 29, 2021
In October, WHO released a consensus definition of post COVID-19 condition that includes 12 domains. This development should lead to better standardization of reporting and contribute to more precise prevalence estimates and better understanding of associated risk factors.
The effects of Variants of Concern (VoC) and COVID vaccination on progression of Long COVID symptoms remains unclear.
Risk factors for developing Long COVID symptoms were similar but limited evidence suggests that pre-pandemic psychological distress and poor general health were associated with developing persistent symptoms. Evidence is too limited to determine whether vaccination reduces the risk of developing Long COVID among persons with breakthrough infections.
Given the protean manifestations of Long COVID symptoms, the underlying causes are likely multifactorial; however, strong evidence to substantiate the theories of causation remains limited.
Research related to longer-term consequences of SARS CoV-2 infections in pediatric populations is growing but remains limited.
Key Findings
March 15, 2021
There is a lack of consensus around the clinical definition of Long COVID which in turn causes challenges with understanding the incidence and prevalence as well as the potential impact for the health care system
Information about the natural history of Long COVID is incomplete but limited evidence suggests that the immune response trajectories differ for those with few or no symptoms compared to those with severe disease. Individuals with severe disease are more likely to exhibit immunological marker abnormalities but anyone can experience functional limitations.
The mechanisms underlying the development of persistent symptoms in Long COVID remain an enigma. Despite multiple theories, there is little empirical evidence for specific immunological and or biochemical abnormalities in samples of individuals with symptoms consistent with Long COVID.
Risk factors for Long COVID include female gender, older age, higher body mass index, pre-existing asthma and the number of symptoms.
Few studies explored the short-term impact of Long COVID on health care utilization patterns and found a higher impact for those with severe disease compared with mild disease.
Category
Healthcare Services
Clinical Presentation
Subject
Long Covid
Clinical Presentation
Health Planning
Symptoms
Population
All
Clinical Setting
Ambulatory
Long Term Care
Primary care
Priority Level
Level 5 Four weeks+ (28 days+)
Cite As
Williams-Roberts, H; Groot, G; Mueller, M; Dalidowicz, M. Long COVID: What does it mean for the healthcare system and programs? 2021 Oct 29. Document no.: EOC021901v2 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2021. 14 p. (CEST rapid review report).
Related Documents
Documents
Less detail